CHICAGO -- The neurokinin-targeted agent elinzanetant significantly reduced the frequency of hot flashes among women receiving endocrine therapy for hormone receptor (HR)-positive breast cancer or its prevention, the phase III OASIS-4 trial showed.

From a baseline of a mean 11.4 daily moderate-to-severe episodes of vasomotor symptoms in the elinzanetant group and 11.5 in the placebo group, mean changes in episodes were -6.5 in the elinzanetant group and -3.0 in the placebo group ( P <0.001) at 4 weeks, reported Fatima Cardoso, MD, of the Champalimaud Clinical Center in Lisbon, Portugal, at the American Society of Clinical Oncology (ASCO) annual meeting.

At week 12, the mean change was -7.8 episodes among those receiving elinzanetant and -4.2 episodes among those receiving placebo (

See Full Page